Details of Disease

General Information of Disease (ID: DISK72WC)

• Disease Name: Dry eye disease
• Disease Class: 9E1Z: Visual system disease
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISK72WC: Dry eye disease
• ICD Code:
  ICD-11: ICD-11: 9E1Z
  ICD-9: ICD-9: 370.33
  Expand ICD-9: 370.33

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
lifitegrast	DM4WVC5	Approved	Small molecular drug	[1]
Luliconazole	DMT73J8	Approved	Small molecular drug	[2]
Perfluorohexyloctane	DMU3U2T	Approved	NA	[3]
Secukinumab	DMYXT2U	Approved	Monoclonal antibody	[4]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Diquafosol	DM64QG9	Phase 3	Small molecular drug	[5]
Tivanisiran	DM95IPS	Phase 3	Small interfering RNA	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [2] Clinical pipeline report, company report or official report of Topica Pharmaceuticals.
• [3] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216675
• [4] ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1736).
• [6] ClinicalTrials.gov (NCT04819269) Tivanisiran for Dry Eye in Subjects With Sjogren's Syndrome. U.S. National Institutes of Health.